TY - JOUR
T1 - Sudden cardiac death after acute heart failure hospital admission
T2 - insights from ASCEND-HF
AU - Pokorney, Sean D.
AU - Al-Khatib, Sana M.
AU - Sun, Jie Lena
AU - Schulte, Phillip
AU - O'Connor, Christopher M.
AU - Teerlink, John R.
AU - Armstrong, Paul W.
AU - Ezekowitz, Justin A.
AU - Starling, Randall C.
AU - Voors, Adriaan A.
AU - Velazquez, Eric J.
AU - Hernandez, Adrian F.
AU - Mentz, Robert J.
N1 - Funding Information:
This work was supported by Scios Inc. (Mountain View, CA, USA), who provided financial and material support for the ASCEND-HF trial. The interpretation of these data and the decision to publish these data were at the sole discretion of the authors. Conflict of interest: S.D.P. reports modest educational grant support from Astra Zeneca; modest research grant support from Gilead and Boston Scientific; modest Consultant/Advisory Board from Boston Scientific and Medtronic. C.M.O. reports consultant fees/honoraria from Amgen and Actelion Pharmaceuticals, Ltd; ownership/partnership/principal from Biscardia, LLC; research grants from Otsuka, Astellas, Gilead, BG Medicine, Roche Diagnostics, Critical Diagnostics, and ResMed. J.R.T. reports consultant fees and/or research grants from Amgen, Corthera, Cytokinet-ics, Jansen/Scios, Novartis, Sorbent, and Trevena. P.W.A. reports research support from Johnson & Johnson. J.A.E. reports consulting fees from Pfizer, Abbott Laboratories, and Servier; research support from Amgen and Johnson & Johnson. R.C.S. reports consulting fees from Novartis, BioControl, and Medtronic; ownership/partnership/principal in Cardiomems; research support from the National Institutes of Health, Medtronic, Biotronik, Novar-tis, and Thoratec; receipt of benefits from the American Board of Internal Medicine. A.A.V. has received consultancy fees and/or research grants from Alere, Amgen, Anexon, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, Merck, Novartis, Servier, Torrent, and Vifor Pharma. A.F.H. reports consulting fees from Sanofi, Johnson & Johnson, AstraZeneca, and Cortera; research support from Amylin and Scios/Johnson & Johnson. R.J.M. reports research support from Amgen, AstraZeneca, BMS, GSK, Gilead, Novartis, Otsuka, and ResMed; honoraria from Thoratec. The other authors report no disclosures.
Publisher Copyright:
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
PY - 2018/3
Y1 - 2018/3
N2 - Aims: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. Methods and results: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan–Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%–0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%–0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%–1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8–9.1, P < 0.0001). Conclusions: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
AB - Aims: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. Methods and results: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan–Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%–0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%–0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%–1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8–9.1, P < 0.0001). Conclusions: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
KW - Heart failure
KW - Implantable cardioverter-defibrillator
KW - Sudden cardiac death
KW - Ventricular fibrillation
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85044298271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044298271&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1078
DO - 10.1002/ejhf.1078
M3 - Article
C2 - 29266564
AN - SCOPUS:85044298271
SN - 1388-9842
VL - 20
SP - 525
EP - 532
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 3
ER -